Investors of Revance Therapeutics Warned: Key Lawsuit Deadline Approaches

The Law Offices of Howard G. Smith remind investors that the deadline to file a lead plaintiff motion in the class action lawsuit for Revance Therapeutics, Inc. (“Revance” or the “Company”) is March 4, 2025. This lawsuit concerns investors who purchased Revance securities between February 29, 2024, and December 6, 2024 (the “Class Period”).

ARE YOU AN INVESTOR WHO LOST MONEY IN REVANCE THERAPEUTICS (RVNC)? CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO JOIN IN THE SECURITIES FRAUD LAWSUIT.

To discuss your legal rights, contact the Law Offices of Howard G. Smith via email at howardsmith@howardsmithlaw.com, by phone at (215) 638-4847, or visit our website at www.howardsmithlaw.com.

Overview of Events

On September 23, 2024, Revance informed the U.S. Securities and Exchange Commission about a notice regarding multiple alleged material breaches. These included issues with buffer stock levels and the promotion of Teoxane products under an exclusive distribution agreement with Teoxane SA. Furthermore, Revance revealed that due to these discussions, Crown Laboratories, Inc. (“Crown”) had decided to delay its tender offer previously announced.

Following this disclosure, Revance’s stock price dropped by $0.44, a decline of 7.7%, closing at $5.37 per share on September 23, 2024, ultimately impacting investors negatively.

On December 9, 2024, Revance announced an amendment to its merger agreement with Crown. The announcement detailed that Crown would soon pursue a tender offer to acquire Revance’s outstanding common stock at a significantly reduced price of $3.10 per share, over a 50% decline from previous valuations.

In response, Revance’s stock price fell further by $0.79, marking a decrease of 20.7%, closing at $3.03 per share on December 9, 2024, further harming investors.

Details of the Lawsuit

The lawsuit accuses the Defendants of making false or misleading statements and failing to disclose significant negative information concerning the business and future outlook of Revance during the Class Period. The complaint outlines that the Defendants did not inform investors that: (1) Revance was in significant breach of its Distribution Agreement; (2) this breach increased the risk of litigation, financial loss, and reputational damage; (3) these issues raised concerns that the Tender Offer would be delayed or altered, and (4) consequently, the Defendants’ positive claims about Revance’s business lacked a sound basis.

If you purchased Revance securities during the Class Period, you may request the Court appoint you as lead plaintiff by March 4, 2025, provided you meet certain legal criteria.

Get in Touch to Participate or Learn More:

For further information regarding this class action, or if you have any questions about your interests or rights, please contact us at:

Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: howardsmith@howardsmithlaw.com
Visit our website at: www.howardsmithlaw.com.

You do not have to take any action to be a member of the class action at this time; you can choose to retain your own counsel or do nothing and remain an absent member of the action.

This announcement may be considered Attorney Advertising in particular jurisdictions in line with applicable laws and ethical guidelines.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250108868480/en/

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com